Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease

Crystal, 1998, Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease, Neurology, 38, 1682, 10.1212/WNL.38.11.1682

Katzman, 1988, Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques, Ann Neurol, 23, 138, 10.1002/ana.410230206

Dickson, 1991, Identification of normal and pathological aging in prospectively studied nondemented elderly humans, Neurobiol Aging, 13, 179, 10.1016/0197-4580(92)90027-U

Arrigada, 1992, Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease, Neurology, 42, 1681, 10.1212/WNL.42.9.1681

Lue, 1996, Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration, J Neuropathol Exp Neurol, 55, 1083, 10.1097/00005072-199655100-00008

Blessed, 1968, The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects, Br J Psychiatry, 114, 797, 10.1192/bjp.114.512.797

Dekosky, 1995, Searching for the holy grail. What is the structural correlate of cognition?, Neurobiol Aging, 16, 285, 10.1016/0197-4580(95)00011-3

Dickson, 1995, Apolipoprotein E immunoreactivity is increased in amyloid deposits of Alzheimer's disease, but not pathological aging or diffuse Lewy body disease, 371

Mirra, 1991, The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479

Braak, 1991, Neuropathological staging of Alzheimer-related changes, Acta Neuropathol, 82, 239, 10.1007/BF00308809

Scheff, 1990, Quantitative assessment of cortical synaptic density in Alzheimer's disease, Neurobiol Aging, 11, 29, 10.1016/0197-4580(90)90059-9

Terry, 1991, Physical basis of cognitive alteration in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol, 30, 572, 10.1002/ana.410300410

Kuo, 1998, Elevated low density lipoprotein in Alzheimer's disease correlates with brain Aβ 42 levels, Biochem Biophys Res Commun, 252, 711, 10.1006/bbrc.1998.9652

Gowing, 1994, Chemical characterization of Aβ17–42 peptide, a component of the diffuse amyloid deposits of Alzheimer's disease, J Biol Chem, 269, 10987, 10.1016/S0021-9258(19)78080-6

Kuo, 1996, Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains, J Biol Chem, 271, 4077, 10.1074/jbc.271.8.4077

Galasko, 1998, High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype, Arch Neurol, 55, 937, 10.1001/archneur.55.7.937

Wisniewski, 1989, Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease, Acta Neuropathol, 78, 337, 10.1007/BF00688170

Otvos, 1994, Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404, J Neurosci Res, 39, 669, 10.1002/jnr.490390607

Su, 1996, Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments, Brain Res, 739, 79, 10.1016/S0006-8993(96)00811-6

Harrington, 1994, Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types: significance for etiological theories of Alzheimer's disease, Am J Pathol, 145, 1472

Hixson, 1990, Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI, J Lipid Res, 31, 545, 10.1016/S0022-2275(20)43176-1

Sparks, 1996, Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients, J Neurol Sci, 138, 97, 10.1016/0022-510X(96)00008-1

Joachim, 1992, The seminal role of β-amyloid in the pathogenesis of Alzheimer's disease, Alz Dis Assoc Disord, 6, 7, 10.1097/00002093-199205000-00003

Tagliavini, 1988, Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals, Neurosci Lett, 93, 191, 10.1016/0304-3940(88)90080-8

Delaere, 1990, Large amounts of neocortical βA4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person, Neurosci Lett, 116, 87, 10.1016/0304-3940(90)90391-L

Teller, 1996, Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome, Nature Med, 2, 93, 10.1038/nm0196-93

Lambert, 1998, Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins, Proc Natl Acad Sci USA, 95, 6448, 10.1073/pnas.95.11.6448

Oda, 1995, Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1–42) and forms slowly sedimenting Aβ complexes that cause oxidative stress, Exp Neurol, 136, 22, 10.1006/exnr.1995.1080

Roher, 1993, β-Amyloid-(42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease, Proc Natl Acad Sci USA, 90, 10836, 10.1073/pnas.90.22.10836

Ishii, 1997, Aβ40 but not Aβ42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease, Brain Res, 748, 250, 10.1016/S0006-8993(96)01363-7

Greenberg, 1996, Apolipoprotein E ε4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy, Stroke, 27, 1333, 10.1161/01.STR.27.8.1333

Alonzo, 1998, Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels, J Neuropathol Exp Neurol, 57, 353, 10.1097/00005072-199804000-00008

Olichney, 1996, The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant, Neurology, 47, 190, 10.1212/WNL.47.1.190